Business Description
Krystal Biotech Inc
NAICS : 325412
SIC : 2836
ISIN : US5011471027
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 72.8 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 44.49 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | -10.1 | |||||
3-Year FCF Growth Rate | -18.5 | |||||
3-Year Book Growth Rate | 23 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 126.93 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 36.82 | |||||
9-Day RSI | 38.73 | |||||
14-Day RSI | 41.54 | |||||
6-1 Month Momentum % | 6.25 | |||||
12-1 Month Momentum % | 40.47 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.5 | |||||
Quick Ratio | 9.33 | |||||
Cash Ratio | 7.79 | |||||
Days Inventory | 280.98 | |||||
Days Sales Outstanding | 110.37 | |||||
Days Payable | 150.17 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.7 | |||||
Shareholder Yield % | -0.75 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 93.07 | |||||
Operating Margin % | 2.42 | |||||
Net Margin % | 63.73 | |||||
FCF Margin % | -13.9 | |||||
ROE % | 13.85 | |||||
ROA % | 13.03 | |||||
ROIC % | 1.63 | |||||
3-Year ROIIC % | -23.23 | |||||
ROC (Joel Greenblatt) % | 60.86 | |||||
ROCE % | 14.79 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 54.31 | |||||
Forward PE Ratio | 30.93 | |||||
PE Ratio without NRI | 118.89 | |||||
Price-to-Owner-Earnings | 307.25 | |||||
PS Ratio | 35.04 | |||||
PB Ratio | 6.8 | |||||
Price-to-Tangible-Book | 7.38 | |||||
EV-to-EBIT | 44.45 | |||||
EV-to-Forward-EBIT | 21.95 | |||||
EV-to-EBITDA | 42.2 | |||||
EV-to-Forward-EBITDA | 21.95 | |||||
EV-to-Revenue | 30.52 | |||||
EV-to-Forward-Revenue | 10.36 | |||||
EV-to-FCF | -226.71 | |||||
Price-to-Projected-FCF | 642.32 | |||||
Price-to-Graham-Number | 6.5 | |||||
Price-to-Net-Current-Asset-Value | 10.25 | |||||
Price-to-Net-Cash | 12.87 | |||||
Earnings Yield (Greenblatt) % | 2.25 | |||||
FCF Yield % | -0.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Krystal Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 153.586 | ||
EPS (TTM) (€) | 3.418 | ||
Beta | -0.43 | ||
Volatility % | 56.65 | ||
14-Day RSI | 41.54 | ||
14-Day ATR (€) | 3.247733 | ||
20-Day SMA (€) | 173.8225 | ||
12-1 Month Momentum % | 40.47 | ||
52-Week Range (€) | 88.5 - 196.4 | ||
Shares Outstanding (Mil) | 28.73 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Krystal Biotech Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Krystal Biotech Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Krystal Biotech Inc Frequently Asked Questions
What is Krystal Biotech Inc(FRA:4KB)'s stock price today?
When is next earnings date of Krystal Biotech Inc(FRA:4KB)?
Does Krystal Biotech Inc(FRA:4KB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |